MicroRNAs in the Pathogenesis, Diagnosis, Prognosis and Targeted Treatment of Cutaneous T-Cell Lymphomas

Maria Gluud, Andreas Willerslev-Olsen, Lise Mette Rahbek Gjerdrum, Lise M Lindahl, Terkild B Buus, Mads Hald Andersen, Charlotte Menne Bonefeld, Thorbjorn Krejsgaard, Ivan V Litvinov, Lars Iversen, Jürgen C Becker, Jenny L Persson, Sergei B Koralov, Thomas Litman, Carsten Geisler, Anders Woetmann, Niels Odum

27 Citationer (Scopus)


Cutaneous T-cell lymphoma (CTCL) represents a heterogeneous group of potentially devastating primary skin malignancies. Despite decades of intense research efforts, the pathogenesis is still not fully understood. In the early stages, both clinical and histopathological diagnosis is often difficult due to the ability of CTCL to masquerade as benign skin inflammatory dermatoses. Due to a lack of reliable biomarkers, it is also difficult to predict which patients will respond to therapy or progress towards severe recalcitrant disease. In this review, we discuss recent discoveries concerning dysregulated microRNA (miR) expression and putative pathological roles of oncogenic and tumor suppressive miRs in CTCL. We also focus on the interplay between miRs, histone deacetylase inhibitors, and oncogenic signaling pathways in malignant T cells as well as the impact of miRs in shaping the inflammatory tumor microenvironment. We highlight the potential use of miRs as diagnostic and prognostic markers, as well as their potential as therapeutic targets. Finally, we propose that the combined use of miR-modulating compounds with epigenetic drugs may provide a novel avenue for boosting the clinical efficacy of existing anti-cancer therapies in CTCL.

Udgave nummer5
Sider (fra-til)1229
StatusUdgivet - 13 maj 2020


Dyk ned i forskningsemnerne om 'MicroRNAs in the Pathogenesis, Diagnosis, Prognosis and Targeted Treatment of Cutaneous T-Cell Lymphomas'. Sammen danner de et unikt fingeraftryk.